LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Variant classification summary
NM_004364.3:c.576G>T
CEBPA
· NP_004355.2:p.(Pro192=)
· NM_004364.3
GRCh37: chr19:33792745 C>A
·
GRCh38: chr19:33301839 C>A
Gene:
CEBPA
Transcript:
NM_004364.3
Final call
VUS
PM2 moderate
BP4 supporting
Variant details
Gene
CEBPA
Transcript
NM_004364.3
Protein
NP_004355.2:p.(Pro192=)
gnomAD AF
3.876660179721966e-06 (v4.1)
ClinVar
Likely benign
OncoKB
Unknown Oncogenic Effect
Classification rationale
Interpretation summary
Generated evidence synthesis
1
PM2 moderate: gnomAD v4.1 grpmax FAF is 0.003892%, below the 0.01% cutoff.
2
BP4 supporting: SpliceAI maximum delta 0.003 is below the 0.1 no-impact threshold.
Final determination:
Under generic ACMG/AMP 2015 rules, one Moderate criterion and one Supporting criterion do not satisfy any pathogenic or benign combination, so the final call is VUS.
Criteria assessment
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
| Criterion | Status | Rationale | Evidence used |
|---|---|---|---|
| PVS1 | N/A | Not applicable: PVS1 requires a null variant (nonsense, frameshift, canonical splice, start-loss or stop-loss), and this is a synonymous variant. |
pvs1_generic_framework
generic_acmg_combination_rules
|
| PS1 | N/A | Not applicable: PS1 requires a missense variant, and this is a synonymous variant. |
generic_acmg_combination_rules
|
| PS2 | Not assessed | Not assessed: no documented affected proband, family-history status, or confirmed maternity and paternity is available for this variant. |
|
| PS3 | Not assessed | Not assessed: no variant-specific functional assay was identified, and the only quantitative result was computational SpliceAI prediction (maximum delta score 0.003). |
generic_acmg_combination_rules
PMID:25741868
PMID:31189880
|
| PS4 | Not assessed | Not assessed: no affected-case and control counts, odds ratio, or confidence interval are available to evaluate the PS4 >5.0 and CI-not-including-1.0 requirements. |
PMID:24121147
gnomad_v4
|
| PM1 | N/A | Not applicable: PM1 requires a missense variant, and this is a synonymous variant. |
generic_acmg_combination_rules
|
| PM2 | Met | Met at Moderate: gnomAD v4.1 grpmax FAF is 0.003892%, below the 0.01% PM2 cutoff, with five alleles and no homozygotes; gnomAD v2.1 is absent. |
gnomad_v2
gnomad_v4
PMID:25741868
|
| PM3 | N/A | Not applicable: CEBPA familial acute myeloid leukemia is described as autosomal dominant, whereas PM3 is restricted to recessive disorders with confirmed trans phase. |
|
| PM4 | N/A | Not applicable: PM4 requires a protein-length change, and this is a synonymous variant. |
pvs1_generic_framework
generic_acmg_combination_rules
|
| PM5 | N/A | Not applicable: PM5 requires a missense variant, and this is a synonymous variant. |
generic_acmg_combination_rules
|
| PM6 | Not assessed | Not assessed: no assumed de novo occurrence or parental testing information is documented for this variant. |
|
| PP1 | Not assessed | Not assessed: no affected relatives, genotypes, or segregation data are documented for this variant. |
|
| PP2 | N/A | Not applicable: PP2 requires a missense variant, and this is a synonymous variant. |
generic_acmg_combination_rules
|
| PP3 | Not met | Not met: synonymous-variant SpliceAI max delta 0.003 is below the PP3 threshold of >=0.2. |
spliceai
PMID:25741868
|
| PP4 | Not assessed | Not assessed: no patient phenotype or family history is available that demonstrates high specificity for a disease with a single genetic etiology. |
|
| PP5 | Not met | Not met: ClinVar has 0 expert-panel submissions, and its non-expert Likely benign assertions cannot trigger PP5. |
clinvar
|
| BA1 | Not met | Not met: gnomAD v4.1 grpmax FAF is 0.003892%, far below the 5% BA1 threshold, despite a South Asian point estimate of 0.01003%. |
gnomad_v4
gnomad_v2
|
| BS1 | Not met | Not met: gnomAD v4.1 grpmax FAF is 0.003892%, below the generic 1% BS1 threshold and therefore does not indicate an excessive disease frequency. |
gnomad_v4
PMID:28518168
|
| BS2 | N/A | Not applicable: BS2 requires an early-onset, fully penetrant disorder, whereas CEBPA-associated AML has age-dependent penetrance and no exact-variant healthy-adult assessment is documented. |
gnomad_v4
|
| BS3 | Not assessed | Not assessed: no validated experimental evidence shows that CEBPA c.576G>T preserves protein function or splicing; SpliceAI is computational only. |
generic_acmg_combination_rules
PMID:25741868
PMID:31189880
|
| BS4 | Not assessed | Not assessed: no tested affected relatives lacking the variant are documented, so non-segregation cannot be evaluated. |
|
| BP1 | N/A | Not applicable: BP1 requires a missense variant, and this is a synonymous variant. |
generic_acmg_combination_rules
|
| BP2 | Not assessed | Not assessed: no documented cis/trans phase result or pathogenic partner variant is available for this synonymous CEBPA variant. |
|
| BP3 | N/A | Not applicable: BP3 requires an in-frame indel in a repeat region, and this is a synonymous variant. |
pvs1_generic_framework
generic_acmg_combination_rules
|
| BP4 | Met | Met at supporting: synonymous-variant SpliceAI max delta 0.003 meets the BP4 threshold of <=0.1. |
spliceai
PMID:25741868
|
| BP5 | Not assessed | Not assessed: no case documents this variant together with a confirmed alternate molecular basis for the relevant disease. |
|
| BP6 | Not met | Not met: ClinVar has 0 expert-panel submissions, so its non-expert Likely benign classifications cannot trigger BP6. |
clinvar
|
| BP7 | Not assessed | Not assessed: SpliceAI max delta 0.003 supports no splice impact, but BP7's required nucleotide-conservation assessment is unavailable. |
spliceai
PMID:25741868
|
Disclaimer:
The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.